TTTran Tran

Tran Tran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tran Tran has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Reda

    Midwestern Univ Chicago, Coll Pharm, Downers Grove, IL USA

    1 shared publication
  • Arti Phatak

    Department of Pharmacy Practice, Midwestern University, Chicago College of Pharmacy, 555 31st Street, Downers Grove, IL, United States

    1 shared publication
  • Brooke L. Griffin

    Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois

    1 shared publication
  • Cynthia P. Koh-Knox Sharp

    Purdue University, College of Pharmacy, West Lafayette, Indiana

    1 shared publication
  • Daniel Ventricelli

    University of Sciences, Philadelphia, Pennsylvania

    1 shared publication
  • Denise M. Kolanczyk

    Department of Pharmacy Practice, Midwestern University, Chicago College of Pharmacy, 555 31st Street, Downers Grove, IL, United States

    1 shared publication

Latest Publications

  • The substance use intervention team: A hospital-based intervention and outpatient clinic to improve care for patients with substance use disorders

    by Tran H Tran, Henry Swoboda, Katy Perticone, Elisabeth Ramsey, Hale Thompson, Kristin Hill, Niranjan S Karnik

    Purpose: In response to the opioid crisis, public health advocates urge hospitals to perform substance use disorder (SUD) screening, brief intervention, discharge planning with referral to treatment, and naloxone education. Universal screening makes specialized treatment available to all patients and decreases stigma around SUDs, allowing patients and providers to address SUDs during their hospitalization. Additionally, hospital and emergency department–initiated medications to treat SUD improve patient engagement with treatment and decrease opioid use, and use of medications for opioid use disorder after nonfatal overdoses decreases mortality. Summary: A substance use intervention team (SUIT) service was established to offer universal screening and consultation by an interdisciplinary team at our urban academic medical center. The SUIT program provides inpatient consultation services as well as medical and behavioral clinic visits to transition patients to long-term treatment and is comprised of physicians, nurse practitioners, a clinical pharmacist, social workers, and a nurse. Successes attributed to enhanced medication use as a function of having a designated pharmacist as an integral member of the team are highlighted. Our medical center initiated screening efforts in tandem with its interdisciplinary team and clinic. The team attempts to start appropriately selected patients with SUD on medications for SUD while hospitalized. From January through December 2018, 87.2% of patients admitted to the hospital received initial SUD screening. Of the patients who screened positive, 1,400 received a brief intervention by a unit social worker; the SUIT service was consulted on 880 patients, and multiple medications for SUD were started during inpatient care. Conclusion: A screening, brief intervention, and referral to treatment service was successfully implemented in our hospital, with the SUIT program in place to provide interdisciplinary addiction care and initiate medications for SUD in appropriate patients.


  • Report of the 2020 Special Committee on Substance Use and Pharmacy Education

    by Tran Tran, Jennifer Ball, Jeffrey P. Bratberg, Edward M. DeSimone, Thomas S. Franko, Lucas G. Hill, Cynthia P. Koh-Knox Sharp, Laura Palombi, Daniel Ventricelli, Dorothy Farrell, et al.

    The 2020 Special Committee on Substance Use and Pharmacy Education was charged to update the work of the 2010 Special Committee on Substance Abuse and Pharmacy Education Report (SAPER) specifically with recommendations on core curricular content and delivery processes on substance misuse and substance use disorder (SUD). This report provides information on the committee’s process to address the charges, background information and resources pertaining to the charges, and rationale for SUD being a critical topic for curriculum at colleges and schools of pharmacy. This committee offers several recommendations to the Association of Colleges of Pharmacy (AACP) pertaining to the committee charges.


  • Barriers to and factors influencing the pursuit of pharmacy student research

    by Milena M. Murray, Denise M. Kolanczyk, Arti Phatak, Justin Schmidt, Mary Ann Kliethermes, Tran Tran, Keri DePatis, Kathleen Vest


  • Management of Breakthrough Pain in Hospitalized Older Adults

    by Tran H. Tran, Anne Reda

    OBJECTIVE: The appropriateness of analgesic administrations based on pain score and medication order in older adults during hospitalization was evaluated. SETTING: As-needed analgesic administrations for geriatric patients on hospitalist general medicine services at a largeuniversity-affiliated medical center from January 1 to March 31, 2015, were included. PRACTICE DESCRIPTION: The hospital is a level one trauma center with more than 500 beds serving an area of more than 500,000 people, 12% of whom are 65 years of age or older. At our institution, breakthrough pain is treated with as-needed analgesic medications based on pain scores specified by the ordering provider. Medication should be given according to which order contains the patient-reported severity of pain. PRACTICE INNOVATION: This is an institutional review board-approved retrospective chart review of 430 analgesic medication administrations in hospitalized older adults. MAIN OUTCOME MEASUREMENTS: Incidence of appropriate medication administration based on pain score report and active medication orders. RESULTS: As-needed analgesic medications were given appropriately 44% of the time based on patient-reported pain score and active medication order. An active medication order was missing to treat the pain score reported by the patient 29% of the time. Out of 430 analgesic administrations, improvement in pain occurred 26% of the time. Pain was reassessed one hour after administration for almost 33% of the orders. Of those, 73% showed an improvement in pain score. CONCLUSION: Our results demonstrate a large discrepancy for hospitalized older adults in what medication is administered compared with what is ordered for as-needed pain treatment. Missing orders contributed to almost one third of inappropriate medication administrations.

  • Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women

    by Tran H. Tran, Brooke L. Griffin, Rebecca H. Stone, Kathleen M. Vest, Timothy J. Todd

    Pregnant women with opioid use disorder can be treated with methadone, buprenorphine, or naltrexone to reduce opioid use and improve retention to treatment. In this review, we compare the pregnancy outcomes of methadone, buprenorphine, and naltrexone in clinical trials and discuss the potential behavioral and developmental effects of these agents seen in offspring in animal studies. Important clinical considerations in the management of opioid use disorder in pregnant women and their infants are also discussed. Outside of pregnancy, buprenorphine is used in combination with naloxone to reduce opioid abuse and diversion. During pregnancy, however, the use of buprenorphine as a single agent is preferred to prevent prenatal naloxone exposure. Both methadone and buprenorphine are widely used to treat opioid use disorder; however, compared with methadone, buprenorphine is associated with shorter treatment duration, less medication needed to treat neonatal abstinence syndrome (NAS) symptoms, and shorter hospitalizations for neonates. Despite being the standard of care, medication‐assisted treatment with methadone or buprenorphine is still underused, making it apparent that more options are necessary. Naltrexone is not a first‐line treatment primarily because both detoxification and an opioid‐free period are required. More research is needed to determine naltrexone safety and benefits in pregnant women. Animal studies suggest that changes in pain sensitivity, developmental processes, and behavioral responses may occur in children born to mothers receiving methadone, buprenorphine, or naltrexone and is an area that warrants future studies.